KeyCorp reaffirmed their buy rating on shares of Teladoc, Inc. (NYSE:TDOC) in a report issued on Sunday. They currently have a $37.00 target price on the health services provider’s stock.

TDOC has been the subject of a number of other reports. Piper Jaffray Companies restated a buy rating and set a $42.00 price objective on shares of Teladoc in a research note on Friday, July 28th. Cowen and Company upped their price objective on Teladoc from $29.00 to $36.00 and gave the stock an outperform rating in a research note on Wednesday, May 31st. BidaskClub cut Teladoc from a hold rating to a sell rating in a research note on Thursday, August 3rd. Zacks Investment Research cut Teladoc from a hold rating to a sell rating in a research note on Monday, July 17th. Finally, Cantor Fitzgerald restated a hold rating on shares of Teladoc in a research note on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $35.82.

Teladoc (TDOC) opened at 35.95 on Friday. Teladoc has a 52-week low of $14.00 and a 52-week high of $37.55. The stock has a 50 day moving average price of $35.08 and a 200 day moving average price of $29.53. The stock’s market cap is $2.04 billion.

Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $44.60 million for the quarter, compared to analysts’ expectations of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.38) earnings per share. Analysts expect that Teladoc will post ($1.44) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teladoc, Inc. (TDOC) Given “Buy” Rating at KeyCorp” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/teladoc-inc-tdoc-given-buy-rating-at-keycorp/1570642.html.

In other Teladoc news, insider Adam C. Vandervoort sold 53,806 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the sale, the insider now directly owns 33,008 shares in the company, valued at $1,020,607.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 4.47% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC raised its stake in Teladoc by 1.3% in the second quarter. FMR LLC now owns 8,209,737 shares of the health services provider’s stock valued at $284,879,000 after buying an additional 106,500 shares during the last quarter. Wellington Management Group LLP raised its stake in Teladoc by 38.9% in the first quarter. Wellington Management Group LLP now owns 4,228,082 shares of the health services provider’s stock valued at $105,701,000 after buying an additional 1,183,435 shares during the last quarter. BlackRock Inc. raised its stake in Teladoc by 42.9% in the second quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after buying an additional 1,154,852 shares during the last quarter. Vanguard Group Inc. raised its stake in Teladoc by 11.5% in the second quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock valued at $105,547,000 after buying an additional 314,646 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in Teladoc by 22.2% in the second quarter. Alliancebernstein L.P. now owns 2,793,590 shares of the health services provider’s stock valued at $96,938,000 after buying an additional 507,390 shares during the last quarter.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.